TRACT Therapeutics

About TRACT Therapeutics

TRACT Therapeutics, Inc. is pioneering a groundbreaking therapy that leverages a patient's own T regulatory cells to better control their immune system post-organ transplant. This innovative approach aims to prevent organ rejection and treat various autoimmune disorders. The company's proprietary platform technology is designed to restore immune balance, potentially reducing the need for second transplants and inducing remission in autoimmune disease patients. TRACT Therapeutics operates in the biopharmaceutical sector, targeting both transplant recipients and individuals with autoimmune conditions. The business model revolves around developing and commercializing personalized therapies, generating revenue through clinical applications and partnerships with healthcare providers. By focusing on personalized medicine, TRACT Therapeutics is poised to transform transplant medicine and autoimmune disease treatment over the next few years.